Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorWeill Medical College of Cornell University

About this trial

The purpose of this study is to obtain biologic materials from the blood, airways and/or urine of normal individuals and individuals with lung disease. The normal are used to establish a set of normal ranges for various parameters. These provide control information when compared to individuals with various pulmonary diseases, and will help in understanding of the etiology and pathogenesis of various lung diseases. The underlying hypothesis is that the pathologic morphological changes in the airway epithelium must be preceded by changes in the gene expression pattern of the airway epithelium and potentially in macrophages.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

All study subjects should be able to provide informed consent

Males or females ages 18 years and older

Must provide HIV informed consent

Must provide informed consent

Disqualifiers

Individuals not deemed in good overall health by the investigator during screening visits and/or prior to the bronchoscopy will not be accepted into the study.

Individuals with history of chronic lung disease, including asthma or with recurrent or recent (within three months) acute pulmonary disease will not be accepted into the study.

Individuals with allergies to atropine or any local anesthetic will not be accepted into the study.

Individuals with allergies to pilocarpine, isoproterenol, terbutaline, atropine or aminophylline will not be accepted into the study.

Trial population

New York Metropolitan area residents

Trial design

Design model

Case-control

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

2,000 Participants
are grouped into 4 trial groups
Group A: 1.1 HEALTHY SUBJECTS
Group B: 1.2 SUBJECTS WITH LUNG DISEASE
Group C: 2. WCMC/NYPH CLINICAL PATIENTS
Group D: 3. PCNY CLINICAL PATIENTS

Trial outcomes

Primary outcomes

1

Establishing normal ranges for various parameters

The primary objective of the study is to obtain biologic materials from the blood, airways and/or urine of normal individuals and individuals with lung disease. The normal are used to establish a set of normal ranges for various parameters. These provide control information when compared to individuals with various pulmonary diseases, and will help in understanding the etiology and pathogenesis of various lung diseases.

Time frame
Participants upon completing the study will be followed up by a phone call seven days after their visit.

Secondary outcomes

1

Learning about the genetic composition of the airway cells

The secondary objective is to learn more about the genetic composition the cells that line the airways (windpipes) of the lungs in normal individuals and in individuals with lung disease.

Time frame
Participants upon completing the study will be followed up by a phone call seven days after their visit.

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Weill Medical College of Cornell University

Lead sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Collaborator

Boehringer Ingelheim

Collaborator

Cystic Fibrosis Foundation

Collaborator